Shifts in the maternal microbiome and immune function occur naturally during the course of pregnancy. However these changes can negatively impact fetal immune and microbiome development. This in turn can increase the potential risk of allergic and autoimmune conditions in later life.
Clinical studies have demonstrated the immune development and microbiome balancing power of OMNi-BiOTiC® PandA with outcomes including reduced risk of infant/childhood allergic and atopic disease (i.e. eczema), reduced colic, and improved maternal gut function and comfort.
This study identified the ability of Omni-Biotic PandA to modulate the production of inflammation influencing cytokines and divert the immune system in a regulatory or tolerant mode.
This study identified the ability of Omni-Biotic PandA to influence immune cell maturation.
Omni-Biotic PandA or a placebo was administered prenatally and for the first year of life to infants genetically predisposed to allergic disease. Infant fecal analyses demonstrated higher levels of beneficial short chain fatty acids and lactate in the probiotic intervention group.
This meta analysis found that probiotics have a protective role in atopic dermatitis (eczema) prevention when administered during the pre- and post-natal period.